Vertex and Alexion Are Schooling Big Biotech

Vertex and Alexion Are Schooling Big Biotech


It's been a pretty miserable year for biotech's biggest names, rife with disappointments and sluggish share-price performance. Not so for two middlewights of the industry: Vertex Pharmaceuticals Inc. and Alexion Pharmaceuticals Inc. Strong earnings reports from Vertex Wednesday afternoon and Alexion Thursday morning capped off what's been a string of largely positive news for the companies, whose market values clock in at a not-quite-top-tier $45 billion and $30 billion, respectively.



from Biotech News